

Supplementary Information for

**Mild and Selective Silicon-mediated Access to Enantioenriched 1,2-Mercaptoamines
and β -Amino arylchalcogenides**

Damiano Tanini*, Cosimo Borgogni, Antonella Capperucci*

*Dipartimento di Chimica "Ugo Schiff", Università di Firenze, Via della Lastruccia 3-13, 50019 Sesto
Fiorentino, Italy. Email: damiano.tanini@unifi.it; antonella.capperucci@unifi.it*

Table of contents

1. General experimental	S2
2. Synthesis and Characterization of new compounds	S3
2.1 Synthesis of <i>N</i> -Tosyl β -aminothiols	S3
2.2 Synthesis of <i>N</i> -Boc β -aminothiols	S5
2.3 Synthesis of β -phenylchalcogenoamines by NRORs of aziridines with phenylchalcogeno silane	S6
3. Copy of NMR spectra of new compounds	S12
4. References	S25

1. General experimental

All reactions were carried out in an oven-dried glassware under inert atmosphere (N_2). Solvents were dried using a solvent purification system (Pure-Solv™). All commercial materials were purchased from various commercial sources and used as received, without further purification. *N*-Ts,¹ *N*-Boc,² *N*-H³ aziridines and silyl chalcogenides⁴ were prepared according to literature reported procedures.

Flash column chromatography purifications were performed with Silica gel 60 (230-400 mesh). Thin layer chromatography was performed with TLC plates Silica gel 60 F₂₅₄, which was visualised under UV light, or by staining with an ethanolic acid solution of *p*-anisaldehyde followed by heating. High resolution mass spectra (HRMS) were recorded by Electrospray Ionization (ESI). GC-MS was performed on a Varian CP 3800/Saturn 2200 instrument.

¹H and ¹³C NMR spectra were recorded in CDCl₃ using Mercury 400, Bruker 400 Ultrashield, and Varian Gemini 200 spectrometers operating at 400 MHz and 200 MHz (for ¹H), 100 MHz and 50 MHz (for ¹³C). ⁷⁷Se NMR spectra were recorded using Bruker 400 Ultrashield and Varian Gemini 200 spectrometers, operating at 76 MHz and 38 MHz, respectively. ¹²⁵Te NMR spectra were recorded in CDCl₃ at 126 MHz with a Bruker Ultrashield 400 Plus instrument. NMR signals were referenced to nondeuterated residual solvent signals (CDCl₃: 7.26 ppm for ¹H, 77.0 ppm for ¹³C). Diphenyl diselenide (PhSe)₂ was used as an external reference for ⁷⁷Se NMR (δ = 461 ppm). (PhTe)₂ was used as an external reference for ¹²⁵Te (δ = 420 ppm). Chemical shifts (δ) are given in parts per million (ppm), and coupling constants (*J*) are given in Hertz (Hz), rounded to the nearest 0.1 Hz. ¹H NMR data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, ap d = apparent doublet, m = multiplet, dd = doublet of doublet, bs = broad singlet, bd = broad doublet, ecc.), coupling constant (*J*) or line separation (ls), and assignment. Where reported, NMR assignments are made according to spin systems, using, where appropriate, APT and 2D NMR experiments (COSY, HSQC) to assist the assignment.


Naming of Compounds. Compound names are those generated by ChemBioDraw 15.0 software (PerkinElmer), following IUPAC nomenclature.

2. Synthesis and Characterization of new compounds

2.1. Synthesis of *N*-Tosyl β -aminothiols (**3a-e**)

General Procedure. A solution of *N*-Tosyl aziridine **1** (0.5 mmol, 1.0 eq.) and bis(trimethylsilyl)sulfide (HMDST, **2**) (0.6 mmol, 1.2 eq.) in dry THF (2 mL) was cooled under inert atmosphere at 0°C, and treated with TBAF (0.12 mL of 1M THF solution, 0.12 mmol). The reaction was stirred for 10 min and then citric acid (50% aq solution) was added. Afterwards, the mixture was diluted with diethyl ether, washed with water, and dried over Na₂SO₄. The solvent was evaporated under vacuum affording compounds **3a-e** pure enough to be used without further purification.

(*S*)-*N*-(1-Mercapto-3-phenylpropan-2-yl)-4-methylbenzenesulfonamide (**3a**)



Following the general procedure, (*S*)-2-benzyl-1-tosylaziridine **1a** (32 mg, 0.11 mmol) and bis(trimethylsilyl)sulfide (24 mg, 0.132 mmol) gave *N*-Tosyl β -aminothiol **3a** (92%, 33 mg) as a yellowish oil.


¹H NMR (200 MHz, CDCl₃): δ = 1.29 (1H, ap t, J = 8.8 Hz, SH), 2.42 (3H, s), 2.54 (1H, ddd, J = 4.0, 8.5, 14.0 Hz, CH_aH_bSH), 2.59-2.68 (1H, m, CH_aH_bSH), 2.70-2.85 (2H, m), 3.53-3.75 (1H, m), 4.71 (1H, d, J = 8.0 Hz, NH), 6.98-7.03 (2H, m), 7.17-7.24 (5H, m), 7.61 (2H, ap d, ls = 8.4 Hz) ppm.

¹³C NMR (50 MHz, CDCl₃): δ = 21.5 (CH₃), 28.7 (CH₂), 38.9 (CH₂), 55.5 (CH), 126.8 (CH), 128.7 (CH), 129.1 (CH), 129.2 (CH), 129.6 (CH), 136.4 (C), 137.2 (C), 143.4 (C) ppm.

MS (EI) m/z (%): 274 [M⁺-CH₂SH, (27)], 230 [M⁺-Bn, (40)], 155 (39), 91 [Bn⁺, (100)], 74 (33), 65 (24).

HRMS (ESI) calc. C₁₆H₁₉NNaO₂S₂ [M+Na]⁺ 344.0755, found 344.0762.

(*S*)-*N*-(1-Mercapto-3-methylpropan-2-yl)-4-methylbenzenesulfonamide (**3b**)



Following the general procedure, (*S*)-2-methyl-1-tosylaziridine **1b** (106 mg, 0.50 mmol) and bis(trimethylsilyl)sulfide (107 mg, 0.60 mmol) gave *N*-Tosyl β -aminothiol **3b** (87%, 107 mg) as a yellowish oil.


¹H NMR (200 MHz, CDCl₃): δ (ppm) = 1.10 (3H, d, J = 6.6 Hz), 1.24 (1H, dd, J = 7.0, 8.4 Hz, SH), 2.43 (3H, s), 2.52-2.59 (2H, m), 3.42-3.61 (1H, m), 5.10 (1H, bs), 7.31 (2H, ap d, ls = 8.2 Hz), 7.77 (2H, ap d, ls = 8.2 Hz).

¹³C NMR (50 MHz, CDCl₃): δ (ppm) = 16.6 (CH₃), 21.5 (CH₃), 34.6 (CH₂), 35.7 (CH), 127.7 (CH), 129.6 (CH), 135.2 (C), 144.3 (C).

MS (EI) m/z (%): 198 [M⁺-CH₂SH, (67)], 155 (65), 91 [Bn⁺, (100)], 65 (22).

HRMS (ESI) calc. C₁₀H₁₅NNaO₂S₂ [M+Na]⁺ 268.0442, found 268.0439.

(*S*)-*N*-(1-Mercapto-3-methylbutan-2-yl)-4-methylbenzenesulfonamide (**3c**)



Following the general procedure, (*S*)-2-isopropyl-1-tosylaziridine **1c** (120 mg, 0.50 mmol) and bis(trimethylsilyl)sulfide (107 mg, 0.60 mmol) gave *N*-Tosyl β -aminothiol **3c** (90%, 123

mg) as a yellowish oil. $[\alpha]_D^{22} = -16.3^\circ$ ($c = 1.8$; CHCl_3).


$^1\text{H NMR}$ (200 MHz, CDCl_3): δ (ppm) = 0.78 (3H, d, $J = 6.6$ Hz, $(\text{CH}_3)_2\text{CH}$), 0.80 (3H, d, $J = 7.0$ Hz, $(\text{CH}_3)_2\text{CH}$), 1.15 (1H, dd, $J = 8.0, 9.4$ Hz, **SH**), 1.79-1.93 (1H, m, $\text{CH}(\text{CH}_3)_2$), 2.42 (3H, s), 2.50 (1H, dd, $J = 5.6, 9.4$ Hz, $\text{CH}_a\text{H}_b\text{SH}$), 2.61 (1H, dd, $J = 5.6, 8.0$ Hz, $\text{CH}_a\text{H}_b\text{SH}$), 3.04-3.15 (1H, m, **CHNH**), 4.94 (1H, bd, $J = 8.8$ Hz, **NH**), 7.29 (2H, ap d, $ls = 8.0$ Hz), 7.76 (2H, ap d, $ls = 8.0$ Hz).

$^{13}\text{C NMR}$ (50 MHz, CDCl_3): δ (ppm) = 18.1 (CH_3), 18.9 (CH_3), 21.5 (CH_3), 27.2 (CH_2), 29.5 (CH), 60.0 (CH), 127.0 (CH), 129.6 (CH), 137.9 (C), 143.4 (C).

MS (EI) m/z (%): 226 [$\text{M}^+ - \text{CH}_2\text{SH}$, (69)], 155 (58), 91 [Bn^+ , (100)], 65 (22).

HRMS (ESI) calc. $\text{C}_{12}\text{H}_{20}\text{NO}_2\text{S}_2$ [$\text{M} + \text{H}$] $^+$ 274.0935, found 274.0921.

N-((2*S*,3*S*)-1-Mercapto-3-methylpentan-2-yl)-4-methylbenzenesulfonamide (**3d**)




Following the general procedure, (*S*)-2-isobutyl-1-tosylaziridine **1e** (51 mg, 0.20 mmol) and bis(trimethylsilyl)sulfide (43 mg, 0.24 mmol) gave *N*-Tosyl β -aminothiol **3e** (91%, 52 mg). $[\alpha]_D^{22} = -13.6^\circ$ ($c = 1.3$; CHCl_3).

$^1\text{H NMR}$ (200 MHz, CDCl_3): δ (ppm) = 0.75-0.83 (6H, m), 1.13 (1H, dd, $J = 7.9, 9.3$ Hz, **SH**), 0.90-1.10 (1H, m), 1.37-1.66 (2H, m), 2.42 (3H, s), 2.45-2.67 (2H, m), 3.12-3.24 (1H, m), 4.94 (1H, d, $J = 8.8$ Hz), 7.30 (2H, ap d, $ls = 8.4$ Hz), 7.76 (2H, ap d, $ls = 8.4$ Hz).

$^{13}\text{C NMR}$ (50 MHz, CDCl_3): δ (ppm) = 11.2 (CH_3), 14.9 (CH_3), 21.5 (CH_3), 24.7 (CH_2), 26.7 (CH_2), 36.3 (CH), 58.6 (CH), 127.0 (CH), 129.7 (CH), 137.8 (C), 143.4 (C).

HRMS (ESI) calc. $\text{C}_{13}\text{H}_{21}\text{NNaO}_2\text{S}_2$ [$\text{M} + \text{Na}$] $^+$ 310.0911, found 310.0919.

(*S*)-*N*-(1-Mercapto-4-methylpentan-2-yl)-4-methylbenzenesulfonamide (**3e**)




Following the general procedure, (*S*)-2-((*S*)-sec-butyl)-1-tosylaziridine **1d** (25 mg, 0.10 mmol) and bis(trimethylsilyl)sulfide (21 mg, 0.12 mmol) gave *N*-Tosyl β -aminothiol **3d** (84%, 24 mg). $[\alpha]_D^{22} = -14.1^\circ$ ($c = 0.8$; CHCl_3).

$^1\text{H NMR}$ (200 MHz, CDCl_3): δ (ppm) = 0.70 (3H, d, $J = 6.4$ Hz), 0.81 (3H, d, $J = 6.4$ Hz), 1.18 (1H, ap t, $J = 8.8$ Hz, **SH**), 1.20-1.30 (2H, m), 1.44-1.52 (1H, m), 2.42 (3H, s), 2.53 (2H, dd, $J = 4.2, 9.0$ Hz), 3.43-3.49 (1H, m), 4.92 (1H, d, $J = 8.4$ Hz), 7.29 (2H, ap d, $ls = 8.4$ Hz), 7.76 (2H, ap d, $ls = 8.4$ Hz).

$^{13}\text{C NMR}$ (50 MHz, CDCl_3): δ (ppm) = 21.3, 21.5, 21.7, 23.3, 27.9, 43.3, 56.6, 127.4, 129.2, 137.8, 142.9.

HRMS (ESI) calc. $\text{C}_{13}\text{H}_{21}\text{NNaO}_2\text{S}_2$ [$\text{M} + \text{Na}$] $^+$ 310.0911, found 310.0925.

N-(2-Mercapto-1-phenylethyl)-4-methylbenzenesulfonamide (**3f**) and *N*-(2-mercapto-2-phenylethyl)-4-methylbenzenesulfonamide (**18**)



Following the general procedure, 2-phenyl-1-tosylaziridine (27 mg, 0.10 mmol) and bis(trimethylsilyl)sulfide (21 mg, 0.12 mmol) gave the mixture of regioisomer **3f** and **18** in a 75:25 ratio.

¹H NMR (300 MHz, CDCl₃): δ (ppm) = *major regioisomer (3f)* 1.13 (1H, ap t, *J* = 8.8 Hz, SH), 2.37 (3H, s), 2.75-2.96 (2H, m, CH₂S), 4.38-4.46 (1H, m), 5.45 (1H, bs), 6.90-7.38 (7H, m), 7.61 (2H, ap d, *l*s = 8.8 Hz); *minor regioisomer (18)* 1.97 (1H, d, *J* = 6.8 Hz, SH), 2.44 (3H, s), 3.29-3.48 (2H, m, CH₂N), 3.94-4.06 (1H, m), 5.45 (1H, bs), 6.90-7.38 (7H, m), 7.61 (2H, ap d, *l*s = 8.8 Hz).


¹³C NMR (50 MHz, CDCl₃): δ (ppm) = 21.5, 31.6 (CH₂S, *major regioisomer*), 43.8 (CHS, *minor regioisomer*), 50.6 (CH₂N, *major regioisomer*), 58.7 (CHN, *major regioisomer*), 126.5, 126.7, 127.0, 127.1, 127.9, 128.0, 128.5, 128.6, 129.0, 129.4, 129.5, 129.8, 137.2, 138.4, 143.8.

MS (ESI, positive) 308.4 [*M*+H]⁺

2.2. Synthesis of *N*-Boc β-aminothiols (6a-c)

General procedure. A solution of aziridine **5** (0.5 mmol, 1.0 eq.) and bis(trimethylsilyl)sulfide (HMDST, **2**) (0.6 mmol, 1.2 eq.) in dry THF (3 mL) was treated with TBAF (0.6 mL of 1M THF solution, 1.2 mmol). The reaction was stirred at room temperature for 1 h and then citric acid (50% *aq* solution) was added. Afterwards, the mixture was diluted with diethyl ether, washed with water, and dried over Na₂SO₄. The solvent was evaporated under vacuum affording the desired *N*-Boc β-aminothiols **6** pure enough to be used without further purification.

(*S*)-*tert*-Butyl (1-mercapto-3-phenylpropan-2-yl)carbamate (6a)




Following the general procedure, *tert*-butyl (*S*)-2-benzylaziridine-1-carboxylate **5a** (70 mg, 0.3 mmol) and bis(trimethylsilyl)sulfide (64 mg, 0.36 mmol) gave the *N*-Boc β-aminothiol **6a** (93%, 75 mg) as a yellowish oil. All recorded spectroscopic data matched those previously reported in the literature.⁵ [α]_D²² = -21.6° (*c* = 0.9; CHCl₃).

¹H NMR (200 MHz, CDCl₃): δ (ppm) = 1.29 (1H, ap t, *J* = 8.8 Hz, SH), 1.42 (9H, s), 2.51-2.77 (2H, m), 2.86 (2H, bd, *J* = 7.2 Hz), 3.87-4.08 (1H, m), 4.76 (1H, d, *J* = 8.0 Hz, NH), 7.17-7.37 (5H, m).

¹³C NMR (50 MHz, CDCl₃): δ (ppm) = 28.4 (CH₃), 37.0 (CH₂), 38.8 (CH₂), 52.6 (CH), 79.5 (C), 126.5 (CH), 128.4 (CH), 129.4 (CH), 137.4 (C), 155.1 (C).

(*S*)-*tert*-Butyl (1-mercapto-3-methylbutan-2-yl)carbamate (6b)




Following the general procedure, *tert*-butyl (*S*)-2-isopropylaziridine-1-carboxylate (46 mg, 0.25 mmol) and bis(trimethylsilyl)sulfide (53 mg, 0.30 mmol) gave the *N*-Boc β-aminothiol **6b** (87%, 48 mg) as a yellowish oil. All recorded spectroscopic data matched those previously reported in the literature.⁶ [α]_D²² = -6.2° (*c* = 1; CHCl₃).

¹H NMR (200 MHz, CDCl₃): δ (ppm) = 0.91 (6H, ap t, *J* = 7.0 Hz, (CH₃)₂CH), 1.29 (1H, dd, *J* = 7.9, 10.8 Hz, SH), 1.44 (9H, s), 1.76-1.92 (1H, m, CH(CH₃)₂), 2.65 (2H, bd, *J* = 6.2, CH₂SH), 3.42-3.61 (1H, m, CHNH), 4.60 (1H, bd, *J* = 9.0 Hz, NH).

^{13}C NMR (50 MHz, CDCl_3): δ (ppm) = 19.4 (CH_3), 19.5 (CH_3), 28.4 (CH_3), 31.2 (CH), 35.9 (CH_2), 54.9 (CH), 79.1 (C), 155.8 (CO).

***tert*-Butyl (S)-(1-mercapto-4-methylpentan-2-yl)carbamate (6c)**




Following the general procedure, *tert*-butyl (S)-2-isobutylaziridine-1-carboxylate (50 mg, 0.25 mmol) and bis(trimethylsilyl)sulfide (53 mg, 0.30 mmol) gave the *N*-Boc β -aminothiol **6c** (76%, 44 mg) as a yellowish oil. All recorded spectroscopic data matched those previously reported in the literature. $[\alpha]_{\text{D}}^{22} = -4.4^\circ$ ($c = 1$; CHCl_3).

2.3. Synthesis of β -phenylchalcogenoamines by NRORs of aziridines with phenylchalcogeno silanes


General procedure. A solution of aziridine (**1**, *N*-Ts aziridine; **5**, *N*-Boc aziridine or **10**, *N*-H aziridine) (0.5 mmol, 1.0 eq.) and phenylchalcogeno silane (**7a**, PhSSiMe_3 ; **7b**, PhSeSiMe_3 ; **7c**, PhTeSiMe_3) (0.6 mmol, 1.2 eq.) in dry THF (3 mL) was treated with TBAF (0.24 mL of 1M THF solution, 0.24 mmol). The reaction was stirred at room temperature for 5-6 h, until complete consumption of starting material was observed by TLC. Afterwards, NH_4Cl (sat. aq solution) was added, the mixture was diluted with diethyl ether, washed with water, and dried over Na_2SO_4 . The solvent was evaporated under vacuum and the crude material was purified by flash column chromatography to afford β -phenylchalcogenoamines **8**, **9** or **11**.

(S)-4-Methyl-*N*-(1-phenyl-3-(phenylthio)propan-2-yl)benzenesulfonamide (8a)




Following the general procedure, (*S*)-2-benzyl-1-tosylaziridine **1a** (43 mg, 0.15 mmol) and (Phenylthio)trimethylsilane **7a** (34 μL , 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 4:1), *N*-Tosyl β -aminophenylsulfide **8a** (89%, 53 mg) as a white solid. Recorded spectroscopic data matched those previously reported in the literature.⁷

***tert*-Butyl (S)-(1-phenyl-3-(phenylthio)propan-2-yl)carbamate (9a)**



Following the general procedure, *tert*-butyl (*S*)-2-benzylaziridine-1-carboxylate **5a** (35 mg, 0.15 mmol) and (Phenylthio)trimethylsilane **7a** (34 μL , 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 8:1), *N*-Boc β -aminophenylsulfide **9a** (76%, 39 mg) as a white solid. Recorded spectroscopic data matched those previously reported in the literature.⁸ $[\alpha]_{\text{D}}^{21} = +23.1^\circ$ ($c = 1$; CH_2Cl_2).


(S)-4-Methyl-*N*-(1-phenyl-3-(phenylselanyl)propan-2-yl)benzenesulfonamide (8b)



Following the general procedure, (*S*)-2-benzyl-1-tosylaziridine **1a** (29 mg, 0.10 mmol) and (Phenylseleno)trimethylsilane **7b** (27 mg, 0.12 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 5:1), *N*-Tosyl β -aminophenylselenide **8b** (92%, 37 mg) as a pale yellowish solid. Recorded spectroscopic data matched those previously


reported in the literature.⁹ $[\alpha]_{\text{D}}^{22} = -51.4^{\circ}$ ($c = 1.2$; CH_2Cl_2).

***tert*-Butyl (*S*)-(1-phenyl-3-(phenylselenanyl)propan-2-yl)carbamate (**9b**)**




Following the general procedure, *tert*-butyl (*S*)-2-benzylaziridine-1-carboxylate **5a** (23 mg, 0.10 mmol) and (Phenylseleno)trimethylsilane **7b** (27 mg, 0.12 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 9:1), *N*-Boc β -aminophenylselenide **9b** (79%, 31 mg). Recorded spectroscopic data matched those previously reported in the literature.⁹ $[\alpha]_{\text{D}}^{21} = +15.1^{\circ}$ ($c = 1.5$; CH_2Cl_2).

(*S*)-4-methyl-*N*-(1-phenyl-3-(phenyltellanyl)propan-2-yl)benzenesulfonamide (8c**)**




Following the general procedure, (*S*)-2-benzyl-1-tosylaziridine **1a** (29 mg, 0.10 mmol) and (Phenyltelluro)trimethylsilane **7c** (34 mg, 0.12 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 5:1), *N*-Tosyl β -aminophenyltelluride **8c** (84%, 42 mg). Recorded spectroscopic data matched those previously reported in the literature.¹⁰ $[\alpha]_{\text{D}}^{20} = -24.8^{\circ}$ ($c = 0.6$; CH_2Cl_2).

***tert*-Butyl (*S*)-(1-phenyl-3-(phenyltellanyl)propan-2-yl)carbamate (**9c**)**




Following the general procedure, *tert*-butyl (*S*)-2-benzylaziridine-1-carboxylate **5a** (35 mg, 0.15 mmol) and (Phenyltelluro)trimethylsilane **7c** (50 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 9:1), *N*-Boc β -aminophenyltelluride **9c** (73%, 48 mg) as a white solid. Recorded spectroscopic data matched those previously reported in the literature.¹¹ $[\alpha]_{\text{D}}^{21} = -15.5^{\circ}$ ($c = 0.7$; CH_2Cl_2).

(*S*)-1-Phenyl-3-(phenylthio)propan-2-amine (11aa**)**




Following the general procedure, (*S*)-2-benzylaziridine **10a** (13 mg, 0.10 mmol) and (Phenylthio)trimethylsilane **7a** (23 μL , 0.12 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β -aminophenylsulfide **11aa** (63%, 15 mg) as a yellowish oil. Recorded spectroscopic data matched those previously reported in the literature.¹² $[\alpha]_{\text{D}}^{21} = +44.7^{\circ}$ ($c = 0.8$; CHCl_3).

(*S*)-1-(Phenylthio)propan-2-amine (11ab**)**




Following the general procedure, (*S*)-2-methylaziridine **10b** (9 mg, 0.15 mmol) and (Phenylthio)trimethylsilane **7a** (34 μL , 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β -aminophenylsulfide **11ab** (56%, 14 mg) as a yellowish oil. Recorded spectroscopic data matched those previously reported in the literature.¹² $[\alpha]_{\text{D}}^{21} = +49.8^{\circ}$ ($c = 1.3$; CHCl_3).

(S)-3-Methyl-1-(phenylthio)butan-2-amine (11ac)




Following the general procedure, (*S*)-2-isopropylaziridine **10c** (13 mg, 0.15 mmol) and (Phenylthio)trimethylsilane **7a** (34 μ L, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β -aminophenylsulfide **11ac** (64%, 19 mg) as a yellowish oil. Recorded spectroscopic data matched those previously reported in the literature.¹² $[\alpha]_D^{21} = -21.2^\circ$ ($c = 0.2$; CHCl₃).

(S)-1-Phenyl-3-(phenylselanyl)propan-2-amine (11ba)



Following the general procedure, (*S*)-2-benzylaziridine **10a** (20 mg, 0.15 mmol) and (Phenylseleno)trimethylsilane **7b** (41 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β -aminophenylselenide **11ba** (65%, 28 mg) as a yellowish oil. Recorded spectroscopic data matched those previously reported in the literature.¹³

(S)-1-(Phenylselanyl)propan-2-amine (11bb)



Following the general procedure, (*S*)-2-methylaziridine **10b** (9 mg, 0.15 mmol) and (Phenylseleno)trimethylsilane **7b** (41 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β -aminophenylselenide **11bb** (55%, 18 mg) as a yellowish oil.


¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.19 (3H, dd, $J = 6.3, 12.4$ Hz), 2.45 (2H, bs, NH₂), 2.84 (1H, dd, $J = 7.7, 12.2$ Hz, CH_aH_bSe), 3.05 (1H, dd, $J = 4.8, 12.2$ Hz, CH_aH_bSe), 3.08-3.16 (1H, m, CHNH₂), 2.24-2.30 (3H, m), 7.52-7.56 (2H, m).

¹³C NMR (100 MHz, CDCl₃): δ (ppm) 23.1, 38.7, 46.7, 127.0, 129.1, 130.0, 132.8.

⁷⁷Se NMR (76 MHz, CDCl₃): δ (ppm) 254.1.


MS (ESI, positive): 238 [M+Na]⁺.

(S)-3-Methyl-1-(phenylselanyl)butan-2-amine (11bc)




Following the general procedure, (*S*)-2-isopropylaziridine **10c** (9 mg, 0.10 mmol) and (Phenylseleno)trimethylsilane **7b** (28 mg, 0.12 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β -aminophenylsulfide **11bc** (62%, 15 mg) as an oil. Recorded spectroscopic data matched those previously reported in the literature.¹⁴ $[\alpha]_D^{22} = +64.2^\circ$ ($c = 0.7$; CHCl₃).

(S)-1-Phenyl-3-(phenyltellanyl)propan-2-amine (11ca)



Following the general procedure, (*S*)-2-benzylaziridine **10a** (20 mg, 0.15 mmol) and (Phenyltelluro)trimethylsilane **7c** (50 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β-aminophenyltelluride **11ca** (63%, 32 mg) as a yellowish oil.¹⁵ $[\alpha]_D^{21} = -55.6^\circ$ ($c = 0.8$; CHCl₃).

(S)-1-(Phenyltellanyl)propan-2-amine (11cb)



Following the general procedure, (*S*)-2-methylaziridine **10b** (9 mg, 0.15 mmol) and (Phenyltelluro)trimethylsilane **7c** (50 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β-aminophenyltelluride **11cb** (58%, 23 mg) as a yellowish oil. $[\alpha]_D^{22} = +28.4^\circ$ ($c = 1.4$; CHCl₃).


¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.23 (3H, d, $J = 6.2$ Hz), 2.31 (2H, bs, NH₂), 2.95 (1H, dd, $J = 7.0, 11.8$ Hz, CH_aH_bTe), 3.11 (1H, dd, $J = 5.2, 11.8$ Hz, CH_aH_bTe), 3.14-3.21 (1H, m, CHNH₂), 7.2-7.24 (2H, m), 7.28-7.32 (1H, m), 7.75-7.78 (2H, m).

¹³C NMR (100 MHz, CDCl₃): δ (ppm) 21.7, 24.3, 47.8, 111.6, 127.7, 129.2, 138.4.

¹²⁵Te NMR (126 MHz, CDCl₃): δ (ppm) 390.5.


MS (ESI, positive): 288 [M+Na]⁺.

(S)-3-Methyl-1-(phenyltellanyl)butan-2-amine (11cc)




Following the general procedure, (*S*)-2-isopropylaziridine **10c** (13 mg, 0.15 mmol) and (Phenyltelluro)trimethylsilane **7c** (50 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β-aminophenylsulfide **11bc** (67%, 29 mg) as an oil. Recorded spectroscopic data matched those previously reported in the literature.¹⁶

(S)-1-(*p*-Tolylthio)propan-2-amine (13a)



Following the general procedure, (*S*)-2-methylaziridine **10b** (9 mg, 0.15 mmol) and trimethyl(*p*-tolylthio)silane **12a** (35 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β-aminosulfide **13a** (58%, 15 mg) as a yellowish oil. Recorded spectroscopic data matched those previously reported in the literature.¹⁷

1-((3-Bromophenyl)thio)propan-2-amine (13b)




Following the general procedure, 2-methylaziridine **10b** (14 mg, 0.24 mmol) and ((3-bromophenyl)thio)trimethylsilane **12b** (75 mg, 0.29 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 1:2), 1-((3-bromophenyl)thio)propan-2-amine **3c** (29 mg, 58%).

¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.18 (3H, d, *J* = 6.3 Hz), 1.86 (2H, bs, NH₂), 2.78 (1H, dd, *J* = 7.9, 13.0 Hz, CH_aH_bS), 3.02 (1H, dd, *J* = 4.7, 13.0, CH_aH_bS), 3.06-3.14 (1H, m, CHNH₂), 7.13 (1H, t, *J* = 7.9 Hz), 7.25- 7.31 (2H, m), 7.48 (1H, apt, *J* = 1.8 Hz).

¹³C NMR (100 MHz, CDCl₃): δ (ppm) 22.8, 43.6, 46.0, 122.7, 127.5, 128.9, 130.1, 131.4, 138.7.

MS (ESI, positive): 246.6 [*M*+H]⁺.

1-((4-Bromophenyl)thio)propan-2-amine (13c)




Following the general procedure, 2-methylaziridine **10b** (14 mg, 0.24 mmol) and ((4-bromophenyl)thio)trimethylsilane **12c** (75 mg, 0.29 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 1:2), 1-((4-bromophenyl)thio)propan-2-amine **13c** (33 mg, 61%).

¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.13 (3H, d, *J* = 6.3 Hz), 1.78 (2H, bs, NH₂), 2.72 (1H, dd, *J* = 8.0, 13.1, CH_aH_bS), 2.96 (1H, dd, *J* = 4.6, 13.1, CH_aH_bS), 2.99-3.08 (1H, m, CHNH₂), 7.18 (2H, apd, *J* = 8.5 Hz), 7.35 (2H, apd, *J* = 8.5 Hz).

¹³C NMR (100 MHz, CDCl₃): δ (ppm) 22.8, 43.9, 45.9, 119.8, 130.89, 131.84, 135.7.

MS (ESI, positive): 246.3 [*M*+H]⁺.

(S)-1-(*p*-Tolylselenanyl)propan-2-amine (16)



Following the general procedure, (*S*)-2-methylaziridine **10b** (9 mg, 0.15 mmol) and trimethyl(*p*-tolylselenanyl)silane **14** (41 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β-aminoselenide **16** (55%, 18 mg) as a yellowish oil.


¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.18 (3H, d, *J* = 6.3 Hz), 2.31 (3H, s), 2.48 (2H, bs, NH₂), 2.79 (1H, dd, *J* = 7.9, 12.3 Hz, CH_aH_bSe), 2.99 (1H, dd, *J* = 4.8, 12.4 Hz, CH_aH_bSe), 3.04-3.12 (1H, m, CHNH₂), 7.07 (2H, ap d, *J* = 8.0 Hz), 7.42 (2H, ap d, *J* = 8.0 Hz).

¹³C NMR (100 MHz, CDCl₃): δ (ppm) 21.1, 23.0, 38.8, 46.7, 125.9, 133.4, 137.2.

⁷⁷Se NMR (76 MHz, CDCl₃): δ (ppm) 246.7.

MS (ESI, positive): 252.0 [*M*+Na]⁺.

(S)-1-(*p*-Tolyltellanyl)propan-2-amine (17)



Following the general procedure, (*S*)-2-methylaziridine **10b** (9 mg, 0.15 mmol) and trimethyl(*p*-tolyltellanyl)silane **15** (53 mg, 0.18 mmol) gave, after flash column chromatography (petroleum ether/EtOAc 1:2), β-aminotelluride **17** (69%, 29 mg) as a yellowish oil.

¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.19 (3H, d, *J* = 6.2 Hz), 2.15 (2H, bs, NH₂), 2.33 (3H, s), 2.87 (1H, dd, *J* = 7.1, 11.0 Hz, CH_aH_bTe), 3.04 (1H, dd, *J* = 5.1, 11.9 Hz, CH_aH_bTe), 3.08-3.15 (1H, m, CHNH₂), 7.01

(2H, ap d, $J = 7.9$ Hz), 7.64 (2H, ap d, $J = 7.09$ Hz).


^{13}C NMR (400 MHz, CDCl_3): δ (ppm) 21.2, 22.0, 24.4, 47.7, 107.3, 130.2, 137.7, 138.8.

^{125}Te (126 MHz, CDCl_3): δ (ppm) 377.1


MS (ESI, positive): 302.1 [$M+\text{Na}$] $^+$.

3. Copy of NMR spectra of new compounds

^1H NMR spectrum of compound **3a** (200 MHz, CDCl_3)




^{13}C NMR spectrum of compound **3a** (50 MHz, CDCl_3)



¹H NMR spectrum of compound **3b** (200 MHz, CDCl₃)

gemini 2


Pulse Sequence: s2pul



¹³C NMR (APT) spectrum of compound **3b** (50 MHz, CDCl₃)

gemini 1


Pulse Sequence: ap:




^1H - ^1H COSY spectrum of compound **3b** (200 MHz, CDCl_3)

gemin1
Pulse Sequence: relayh
Solvent: CDCl_3
Ambient temperature
File: cbf2_COSY
GEMINI-200 "sun4"


Relax. delay 1.000 sec
COSY 90-90
Acq. time 0.142 sec
Width 1799.1 Hz
2D width 1799.1 Hz
8 repetitions
256 increments
OBSERVE H1, 199.9579269 MHz
DATA PROCESSING
Sine bell 0.071 sec
F1 DATA PROCESSING
Sine bell 0.036 sec
FT size 512 x 512
Total time 44 min, 56 sec



^1H NMR spectrum of compound **3c** (200 MHz, CDCl_3)




^{13}C NMR spectrum of compound **3c** (50 MHz, CDCl_3)




^1H - ^1H COSY spectrum of compound **3c** (200 MHz, CDCl_3)

Pulse Sequence: relayh
Solvent: CDCl_3
Ambient temperature
File CB46_COSY
GEMINI-200 "sun4"


Relax. delay 1.000 sec
COSY 90-90
Acq. time 0.140 sec
Width 1633.2 Hz
2D Width 1633.2 Hz
8 repetitions
256 increments
OBSERVE H1, 199.9579269 MHz
DATA PROCESSING
Sine bell 0.070 sec
F1 DATA PROCESSING
Sine bell 0.035 sec
F1 size 512 x 512
Total time 44 min, 48 sec




¹H NMR spectrum of compound **3d** (300 MHz, CDCl₃)




¹³C NMR spectrum of compound **3d** (50 MHz, CDCl₃)




^1H NMR spectrum of compound **11bb** (400 MHz, CDCl_3)




^{13}C NMR spectrum of compound **11bb** (100 MHz, CDCl_3)




^{77}Se NMR spectrum of compound **11bb** (76 MHz, CDCl_3)




^1H NMR spectrum of compound **11cb** (400 MHz, CDCl_3)




^{13}C NMR spectrum of compound **11cb** (100 MHz, CDCl_3)




^{125}Te NMR spectrum of compound **11cb** (126 MHz, CDCl_3)




¹H NMR of compound **13b** (400 MHz, CDCl₃)




¹³C NMR of compound **13b** (100 MHz, CDCl₃)




¹H NMR of compound **13c** (400 MHz, CDCl₃)




¹³C NMR of compound **13c** (100 MHz, CDCl₃)




^1H NMR spectrum of compound **16** (400 MHz, CDCl_3)




^{13}C NMR spectrum of compound **16** (100 MHz, CDCl_3)




^{77}Se NMR spectrum of compound **16** (76 MHz, CDCl_3)




^1H NMR spectrum of compound **17** (400 MHz, CDCl_3)



^{13}C NMR spectrum of compound **17** (100 MHz, CDCl_3)



^{125}Te NMR spectrum of compound **17** (126 MHz, CDCl_3)



4. References

1. M. B. Bieber and M. C. F. de Araujo, *Molecules*, 2002, **7**, 902.
2. H. M. I. Osborn and J. Sweeney, *Tetrahedron: Asymmetry* 1997, **8**, 1693.
3. M. S. I. Veitía, P. L. Brun, P. Jorda, A. Falguières and C. Ferroud, *Tetrahedron: Asymmetry* 2009, **20**, 2077.
4. (a) S. Yamago, K. Iida and J. I. Yoshida. *Tetrahedron Lett.*, 2001, **42**, 5061; (b) K. Sasaki, Y. Aso, T. Otsubo and F. Ogura *Tetrahedron Lett.*, 1985, **26**, 453; (c) S. Kozuka, T. Higashino and T. Kitamura, *Bull. Chem. Soc. Jpn.*, 1981, **54**, 1420.
5. T. Cao, S. Jin, S. Wang, D. Zhang, X. Meng and M. Zhu, *Nanoscale*, 2013, **5**, 7589.
6. V. T. Myllymäki, M. K. Lindvall and A. M. P. Koskinen, *Tetrahedron*, 2001, **57**, 4629.
7. M. Wang, J. Wei, Q. Fan and X. Jiang, *Tetrahedron*, 2016, **72**, 2671.
8. H. Chen, Z. Hu, J. Zhang, G. Liang and B. Xu, *Tetrahedron*, 2015, **71**, 2089.
9. J. Vargas, S. Narayanaperumal, K. Gul, B. B. Ravanello, L. Dornelles, L. C. Soares, C. F.S. Alves, T. Schneider, R. A. Vaucher, R. C.V. Santos and O. E.D. Rodrigues, *Tetrahedron*, 2012, **68**, 10444.
10. A. Angeli, D. Tanini, A. Capperucci and C. T. Supuran, *Bioorg. Chem.*, 2018, **76**, 268.
11. F. Vargas and J. V. Comasseto, *J. Organomet. Chem.*, 2009, **694**, 122.
12. H. Ishibashi, M. Uegaki, M. Sakai and Y. Takeda, *Tetrahedron*, 2001, **57**, 2115.
13. S. M. Salman, S. Narayanaperumal, R. S. Schwab, C. R. Bender, O. E. D. Rodrigues and L. Dornelles, *RSC Adv.*, 2012, **2**, 8478.
14. M. Zielińska-Błajet, R. Siedlecka and J. Skarzewski, *Tetrahedron: Asymmetry*, 2007, **18**, 131.
15. A. L. Braga, R. S. Schwab, E. E. Alberto, S. M. Salman, J. Vargas and J. B. Azeredo, *Tetrahedron Lett.*, 2009, **50**, 2309.
16. D. Tanini, A. Grechi, L. Ricci, S. Dei, E. Teodori, A. Capperucci, *New J. Chem.*, 2018, **42**, 6077.
17. Y. A. Naumovich, A. O. Kokuev, A. Yu. Sukhorukov, S. L. Ioffe, *Synlett*, 2018, **29**, 1334.